Click on a filter below to refine your search. Remove a filter to broaden your search.
“Adult patients with IBD and RSV infection … may benefit from the new RSV vaccine recommended for adults aged 60 years and older,” the authors write.
Vaccination effectiveness did not differ with inverse probability of vaccination weighting or for those aged 60 to 74 years and 75 years and older.
Updated shots to shield against COVID-19 infection were approved by the US Food and Drug Administration on Thursday.
In contrast, post-COVID-19 myocarditis shows outcomes similar to conventional myocarditis.
The approval comes much earlier than last year, when autumn shots were announced in mid-September.
Lower levels of trust were tied to significantly lower odds of COVID-19 and flu vaccination.
A higher proportion of those who received a single dose versus three doses had to urinate five or more times in the night.
Odds ratio of 6.30 for Guillain-Barré syndrome association with SARS-CoV-2 infection and 0.41 for COVID-19 vaccine administration.
A fourth dose reduces the risk for SARS-CoV-2 for patients with systemic autoimmune rheumatic diseases using DMARDs.
The findings compared with placebo at 28-day and 43-day follow-up.